X

Trial Profile

Subcutaneous Cladribine Plus Pegylated Interpheron Alfa-2a in Advanced Systemic Mastocytosis With D816V and Other Exon 17 KIT Mutations.

Status: Recruiting

Phase of Trial: Phase II/III

Latest Information Update: 10 Aug 2018

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cladribine (Primary) ; Peginterferon alfa-2a (Primary)
Indications Leukaemia; Sarcoma; Systemic mastocytosis
Focus Therapeutic Use

Most Recent Events

26 Aug 2016 Planned primary completion date changed from 1 Mar 2013 to 1 Feb 2017.
26 Aug 2016 Planned End Date changed from 1 May 2013 to 1 Jun 2017.
20 Jul 2013 New source identified and integrated (European Clinical Trials Database; EudraCT2012-000797-35).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com